New platform for controlled and sustained delivery of the EGF receptor tyrosine kinase inhibitor AG1478 using poly(lactic-co-glycolic acid) microspheres

References

• Barker AJ, Gibson KH, Grundy W, Godfrey AA, Barlow JJ, Healy MP, Woodburn JR, Ashton SE, Curry BJ, Scarlett L, Henthorn L, Richards L. Studies leading to the identification of ZD1839 (IRESSA): An orally active, selective epidermal growth factor receptor tyrosine kinase inhibitor targeted to the treatment of cancer. Bioorg Med Chem Lett 2001; 11: 1911–1914
   PubMed Web of Science ®Google Scholar
• Busse D, Doughty RS, Ramsey TT, Russell WE, Price JO, Flanagan WM, Shawver LK, Arteaga CL. Reversible G(1) arrest induced by inhibition of the epidermal growth factor receptor tyrosine kinase requires up-regulation of p27(KIP1) independent of MAPK activity. J Biol Chem 2000; 275: 6987–6995
   PubMed Web of Science ®Google Scholar
• Ciardiello F, Tortora G. EGFR antagonists in cancer treatment. N Engl J Med 2008; 358: 1160–1174
   PubMed Web of Science ®Google Scholar
• Cohen MH, Johnson JR, Chen YF, Sridhara R, Pazdur R. FDA drug approval summary: Erlotinib (Tarceva) tablets. Oncologist 2005; 10: 461–466
   PubMed Web of Science ®Google Scholar
• Ellis A, Doherty M, Walker F, Weinstock J, Nerrie M, Vitali A, Murphy R, Johns T, Scott A, Levitzki A, McLachlan G, Webster L, Burgess A, Nice E. Preclinical analysis of the analinoquinazoline AG1478, a specific small molecule inhibitor of EGF receptor tyrosine kinase. Biochem Pharmacol 2006; 71: 1422–1434
   PubMed Web of Science ®Google Scholar
• Ellis A, Nice E, Weinstock J, Levitzki A, Burgess A, Webster L. High-performance liquid chromatographic analysis of the tyrphostin AG1478, a specific inhibitor of the epidermal growth factor receptor tyrosine kinase, in mouse plasma. J Chromatogr B Biomed Sci Appl 2001; 754: 193–199
   PubMedGoogle Scholar
• Erschbamer M, Pernold K, Olson L. Inhibiting epidermal growth factor receptor improves structural, locomotor, sensory, and bladder recovery from experimental spinal cord injury. J Neurosci 2007; 27: 6428–6435
   PubMed Web of Science ®Google Scholar
• Fabricant RN, De Larco JE, Todaro GJ. Nerve growth factor receptors on human melanoma cells in culture. Proc Natl Acad Sci USA 1977; 74: 565–569
   PubMed Web of Science ®Google Scholar
• Fawcett J, Asher R. The glial scar and central nervous system repair. Brain Res Bull 1999; 49: 377–391
   PubMed Web of Science ®Google Scholar
• Fu K, Harrell R, Zinski K, Um C, Jaklenec A, Frazier J, Lotan N, Burke P, Klibanov A, Langer R. A potential approach for decreasing the burst effect of protein from PLGA microspheres. J Pharm Sci 2003; 92: 1582–1591
   PubMed Web of Science ®Google Scholar
• Gullick WJ. Prevalence of aberrant expression of the epidermal growth factor receptor in human cancers. Br Med Bull 1991; 47: 87–98
   PubMed Web of Science ®Google Scholar
• Gupta RK, Chang AC, Griffin P, Rivera R, Guo YY, Siber GR. Determination of protein loading in biodegradable polymer microspheres containing tetanus toxoid. Vaccine 1997; 15: 672–678
   PubMedGoogle Scholar
• Han Y, Caday CG, Nanda A, Cavenee WK, Huang HJ. Tyrphostin AG 1478 preferentially inhibits human glioma cells expressing truncated rather than wild-type epidermal growth factor receptors. Cancer Res 1996; 56: 3859–3861
   PubMed Web of Science ®Google Scholar
• Harari PM. Epidermal growth factor receptor inhibition strategies in oncology. Endocrine-Related Cancer 2004; 11: 689–708
   PubMed Web of Science ®Google Scholar
• Jain R. The manufacturing techniques of various drug loaded biodegradable poly(lactide-co-glycolide) (PLGA) devices. Biomaterials 2000; 21: 2475–2490
   PubMed Web of Science ®Google Scholar
• Jain R, Shah NH, Malick AW, Rhodes CT. Controlled drug delivery by biodegradable poly(ester) devices: Different preparative approaches. Drug Dev Ind Pharm 1998; 24: 703–727
   PubMed Web of Science ®Google Scholar
• Johns TG, Luwor RB, Murone C, Walker F, Weinstock J, Vitali AA, Perera RM, Jungbluth AA, Stockert E, Old LJ, Nice EC, Burgess AW, Scott AM. Antitumor efficacy of cytotoxic drugs and the monoclonal antibody 806 is enhanced by the EGF receptor inhibitor AG1478. Proc Natl Acad Sci USA 2003; 100: 15871–15876
   PubMedGoogle Scholar
• Kari C, Chan TO, Rocha de Quadros M, Rodeck U. Targeting the epidermal growth factor receptor in cancer: Apoptosis takes center stage. Cancer Res 2003; 63: 1–5
   PubMed Web of Science ®Google Scholar
• Koprivica V, Cho K, Park J, Yiu G, Atwal J, Gore B, Kim J, Lin E, Tessier-Lavigne M, Chen D, He Z. EGFR activation mediates inhibition of axon regeneration by myelin and chondroitin sulfate proteoglycans. Science 2005; 310: 106–110
   PubMed Web of Science ®Google Scholar
• Langer R, Folkman J. Polymers for the sustained release of proteins and other macromolecules. Nature 1976; 263: 797–800
   PubMed Web of Science ®Google Scholar
• Levitzki A, Gazit A. Tyrosine kinase inhibition: An approach to drug development. Science 1995; 267: 1782–1788
   PubMed Web of Science ®Google Scholar
• Linggi B, Carpenter G. ErbB receptors: New insights on mechanisms and biology. Trends Cell Biol 2006; 16: 649–656
   PubMed Web of Science ®Google Scholar
• Liu B, Chen H, Johns T, Neufeld A. Epidermal growth factor receptor activation: An upstream signal for transition of quiescent astrocytes into reactive astrocytes after neural injury. J Neurosci 2006; 26: 7532–7540
   PubMed Web of Science ®Google Scholar
• Liu B, Neufeld A. Activation of epidermal growth factor receptor causes astrocytes to form cribriform structures. Glia 2004a; 46: 153–168
   PubMed Web of Science ®Google Scholar
• Liu B, Neufeld A. Activation of epidermal growth factor receptors directs astrocytes to organize in a network surrounding axons in the developing rat optic nerve. Dev Biol 2004b; 273: 297–307
   PubMedGoogle Scholar
• Liu B, Neufeld AH. Activation of epidermal growth factor receptors in astrocytes: From development to neural injury. J Neurosci Res 2007; 85: 3523–3529
   PubMedGoogle Scholar
• Nagane M, Narita Y, Mishima K, Levitzki A, Burgess AW, Cavenee WK, Huang HJ. Human glioblastoma xenografts overexpressing a tumor-specific mutant epidermal growth factor receptor sensitized to cisplatin by the AG1478 tyrosine kinase inhibitor. J Neurosurg 2001; 95: 472–479
   PubMed Web of Science ®Google Scholar
• Neufeld AH, Liu B. Glaucomatous optic neuropathy: When glia misbehave. Neuroscientist Rev J Bringing Neurobiol Neurol Psychiatry 2003; 9: 485–495
   Google Scholar
• Niwa T, Takeuchi H, Hino T, Kunou N, Kawashima Y. Preparations of biodegradable nanospheres of water-soluble and insoluble drugs with -lactide/glycolide copolymer by a novel spontaneous emulsification solvent diffusion method, and the drug release behavior. J Contr Rel 1993; 25: 89–98
   Web of Science ®Google Scholar
• Partik G, Hochegger K, Schörkhuber M, Marian B. Inhibition of epidermal-growth-factor-receptor-dependent signalling by tyrphostins A25 and AG1478 blocks growth and induces apoptosis in colorectal tumor cells in vitro. J Cancer Res Clin Oncol 1999; 125: 379–388
   PubMedGoogle Scholar
• Perera RM, Narita Y, Furnari FB, Gan HK, Murone C, Ahlkvist M, Luwor RB, Burgess AW, Stockert E, Jungbluth AA, Old LJ, Cavenee WK, Scott AM, Johns TG. Treatment of human tumor xenografts with monoclonal antibody 806 in combination with a prototypical epidermal growth factor receptor-specific antibody generates enhanced antitumor activity. Clin Cancer Res 2005; 11: 6390–6399
   PubMed Web of Science ®Google Scholar
• Raymond E, Faivre S, Armand JP, 2000. Epidermal growth factor receptor tyrosine kinase as a target for anticancer therapy. Drugs 60(Suppl 1):15–23; discussion 41–42
   Google Scholar
• Saltzman WM, Fung LK. Polymeric implants for cancer chemotherapy. Adv Drug Deliv Rev 1997; 26: 209–230
   PubMed Web of Science ®Google Scholar
• Segaert S, Van Cutsem E. Clinical signs, pathophysiology and management of skin toxicity during therapy with epidermal growth factor receptor inhibitors. Ann Oncol 2005; 16: 1425–1433
   PubMed Web of Science ®Google Scholar
• Seif R, Cuzin F. Temperature-sensitive growth regulation in one type of transformed rat cells induced by the tsa mutant of polyoma virus. J Virol 1977; 24: 721–728
   PubMed Web of Science ®Google Scholar
• Shive M, Anderson J. Biodegradation and biocompatibility of PLA and PLGA microspheres. Adv Drug Deliv Rev 1997; 28: 5–24
   PubMed Web of Science ®Google Scholar
• Silver J, Miller J. Regeneration beyond the glial scar. Nat Rev Neurosci 2004; 5: 146–156
   PubMed Web of Science ®Google Scholar
• Smith G, Strunz C. Growth factor and cytokine regulation of chondroitin sulfate proteoglycans by astrocytes. Glia 2005; 52: 209–218
   PubMed Web of Science ®Google Scholar
• Stern DF, Roberts AB, Roche NS, Sporn MB, Weinberg RA. Differential responsiveness of myc- and ras-transfected cells to growth factors: Selective stimulation of myc-transfected cells by epidermal growth factor. Mol Cell Biol 1986; 6: 870–877
   PubMed Web of Science ®Google Scholar
• Wang H, Katagiri Y, McCann TE, Unsworth E, Goldsmith P, Yu ZX, Tan F, Santiago L, Mills EM, Wang Y, Symes AJ, Geller HM. Chondroitin-4-sulfation negatively regulates axonal guidance and growth. J Cell Sci 2008; 121: 3083–3091
   PubMed Web of Science ®Google Scholar
• Wong RW, Guillaud L. The role of epidermal growth factor and its receptors in mammalian CNS. Cytokine Growth Factor Rev 2004; 15: 147–156
   PubMed Web of Science ®Google Scholar
• Wrann MM, Fox CF. Identification of epidermal growth factor receptors in a hyperproducing human epidermoid carcinoma cell line. J Biol Chem 1979; 254: 8083–8086
   PubMed Web of Science ®Google Scholar
• Yamaguchi K, Anderson JM. In vivo biocompatability studies of medisorb(R) 65/35 D. L-lactide glycolide coploymer microspheres. 1993, J Contr Rel 24 (1–3):81–93
   Google Scholar
• Yarden Y, Sliwkowski MX. Untangling the ErbB signalling network. Nat Rev Mol Cell Biol 2001; 2: 127–137
   PubMed Web of Science ®Google Scholar
• Yiu G, He Z. Glial inhibition of CNS axon regeneration. Nat Rev Neurosci 2006; 7: 617–627
   PubMed Web of Science ®Google Scholar
• Zhu XF, Liu ZC, Xie BF, Li ZM, Feng GK, Yang D, Zeng YX. EGFR tyrosine kinase inhibitor AG1478 inhibits cell proliferation and arrests cell cycle in nasopharyngeal carcinoma cells. Cancer Lett 2001; 169: 27–32
   PubMedGoogle Scholar
• Zolnik B, Burgess D. Effect of acidic pH on PLGA microsphere degradation and release. J Contr Rel Official J Contr Rel Soc 2007; 122(3)338–334
   PubMed Web of Science ®Google Scholar